{"id":"W4281708097","doi":"10.1200/jco.2022.40.16_suppl.5019","title":"Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Tolerability; Prostate cancer; Hazard ratio; Internal medicine; Interim analysis; Adverse effect; Clinical endpoint; Placebo; Confidence interval; Enzalutamide; Oncology; Clinical trial; Surgery; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002062229,0.0007434998,0.0009084914,0.0002587548,0.0002263416,0.0007879842,0.000440675,0.000564991,0.004237],"category_scores_gemma":[0.001667178,0.0003059122,0.001404,0.0004578961,0.0004235566,0.0006075401,0.0003335531,0.001909096,0.0007399007],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006070154,"about_ca_system_score_gemma":0.001003835,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004861365,"about_ca_topic_score_gemma":0.00142201,"domain_scores_codex":[0.9995344,0.0002766385,0.00003038359,0.00004598451,0.000053157,0.00005951491],"domain_scores_gemma":[0.9987178,0.0003232696,0.0004896863,0.00006232946,0.00008109905,0.000325865],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8225029,0.01610952,0.01859698,0.001500062,0.002300001,0.0003319668,0.0002270548,0.002120301,0.0150932,0.0001351984,0.004708732,0.1163741],"study_design_scores_gemma":[0.4453806,0.4838228,0.05840461,0.0001543132,0.001917811,0.0008150685,0.0001112184,0.001159008,0.002791551,0.000308067,0.005089626,0.00004529093],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893768,0.004365561,0.0005092202,0.0004414465,0.00007709301,0.001056339,0.002100457,0.00006233901,0.002010664],"genre_scores_gemma":[0.9930413,0.001653184,0.0006145518,0.0004115054,0.0001555988,0.0007477646,0.002380038,0.0000143567,0.0009818121],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004237,"threshold_uncertainty_score":0.01417416,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1218570109834301,"score_gpt":0.4446175650949789,"score_spread":0.3227605541115487,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}